Roger Kornu, MD
Rheumatology · Tustin, CANPI 1841386349
Payments from drug & device makers
Across 2,380 payments — averaging $360.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$297K
- AbbVie$210K
- Lilly USA, LLC$110K
- Bristol Myers Squibb$65K
- Novartis$28K
- Eli Lilly$24K
- plus $124K from 26 others
Across 4 payments — averaging $5764.23 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$22K
- AbbVie$1K
What the payments were for
- Consulting fees$129,79616%
- Speaking & faculty fees$534,16267%
- Travel & lodging$84,76111%
- Food & beverage$53,0837%
- Education$1140%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 779 | $296,763 |
| AbbVie | 529 | $210,031 |
| Lilly USA, LLC | 286 | $110,013 |
| Bristol Myers Squibb | 67 | $65,358 |
| Novartis | 102 | $28,426 |
| Eli Lilly | 8 | $24,007 |
| UCB, Inc. | 80 | $23,501 |
| Johnson & Johnson(2 entities) | 149 | $19,536 |
| Janssen Research & Development, LLC | 1 | $18,470 |
| Boehringer Ingelheim | 44 | $13,995 |
| Pfizer | 48 | $11,245 |
| E.r. Squibb & Sons, L.L.C. | 39 | $9,928 |
| AstraZeneca(2 entities) | 67 | $9,853 |
| Gilead | 15 | $9,137 |
| Janssen Scientific Affairs, LLC | 5 | $2,839 |
| Sobi, Inc | 7 | $2,327 |
| GSK | 66 | $1,257 |
| Radius Health, Inc. | 30 | $706 |
| Sanofi | 12 | $351 |
| Aurinia Pharma U.S., Inc. | 8 | $315 |
| Fresenius Kabi USA, LLC | 6 | $175 |
| Mallinckrodt Hospital Products Inc. | 7 | $158 |
| Octapharma USA, Inc. | 4 | $92 |
| Ultragenyx Pharmaceutical Inc. | 4 | $81 |
| Genentech USA, Inc. | 4 | $74 |
| Alvogen Inc | 3 | $68 |
| ANI Pharmaceuticals, Inc. | 2 | $63 |
| Scilex Pharmaceuticals Inc. | 2 | $46 |
| Medexus Pharma, Inc. | 2 | $30 |
| Cumberland Pharmaceuticals, Inc. | 2 | $23 |
| Sanofi-aventis U.S. LLC | 1 | $20 |
| Organon | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$858,907 in reported general payments places this provider in the 95th percentile of 808 rheumatology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EnbrelEtanercept | 12 | $88,271 |
| ForteoTeriparatide | 16 | $81,355 |
| Taltz AutoinjectorIxekizumab | 12 | $79,577 |
| RasuvoMethotrexate/Pf | 15 | $12,517 |
| MethotrexateMethotrexate Sodium | 209 | $9,887 |
| Hydroxychloroquine Sulfate | 153 | $7,347 |
| Leflunomide | 76 | $5,862 |
| Mycophenolate Mofetil | 13 | $4,908 |
| Pregabalin | 43 | $2,984 |
| Prednisone | 211 | $2,325 |
| Sulfasalazine | 72 | $1,813 |
| Celecoxib | 49 | $1,752 |
| Allopurinol | 43 | $1,213 |
| Azathioprine | 12 | $969 |
| Diclofenac Sodium | 21 | $921 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenEnbrel | $296,763 | $88,27112 claims |
| Lilly USA, LLCForteo | $110,013 | $81,35516 claims |
| Medexus Pharma, Inc.Rasuvo | $30 | $12,51715 claims |
| Scilex Pharmaceuticals Inc.Colchicine | $46 | $57911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 808 rheumatology providers in California.
Other rheumatology in Tustin
- Robin DoreTustin$2M
- Samy MetyasCovina$12.9M
- Christine ThaiHuntington Beach$8.5M
- Tien-I SuWhittier$8.4M
- Eric LeeUpland$6.9M
- Orrin TroumSanta Monica$6.9M
- Shirley PangFullerton$5.7M
- William RobinsonStanford$5.1M
- Dan laTujunga$5.1M
- Christina Charles-SchoemanLos Angeles$4.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.